Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11353314 | 0.80 | RAD52 (0.59) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL11001118 | 0.80 | HTT (0.50) | HTTALDH1A1GAALMNANPC1 | |
| SCHEMBL2070769 | 0.80 | ALDH1A1 (0.52) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL6353701 | 0.80 | MAPT (0.59) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL2071884 | 0.80 | GAA (0.59) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL16592515 | 0.80 | GAA (0.59) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL2071192 | 0.79 | CYP1A2 (0.56) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL28577453 | 0.79 | MEN1 (0.74) | ALDH1A1GAALMNANPC1RAB9A | |
| SCHEMBL30738420 | 0.78 | ALDH1A1 (0.72) | HTTALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL5183678 | 0.78 | ALDH1A1 (0.72) | HTTALDH1A1MAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906537-B2 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2011-03-15 | — | — | US | disclosed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | disclosed |
| CN-1761464-A | Substituted p-diaminobenzene derivatives | LUNDBECK & CO AS H (DK) | 2006-04-19 | — | — | CN | disclosed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | ABCB1, UGT2B7, CYP2D6 | HTT 3204/4885ALDH1A1 112/4885MAPT 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.